Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

103.12 +1.50 (+1.48%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
96 97 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
Qualcomm, Merck And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
10 Analysts Have This to Say About Merck & Co
Via Benzinga
Merck & Co Unusual Options Activity For November 03
Via Benzinga
A Look Into Merck & Co Inc's Price Over Earnings
Via Benzinga
7 Biotech Stocks to Buy for Big-Time Gains
Biotech stocks can be big winners because they're at the forefront of scientific innovation and push the boundaries of medical research. 
Via InvestorPlace
7 Safe Stocks to Buy if You Think Q3’s Gangbuster Growth Won’t Last
Although the Q3 U.S. GDP print came in much hotter than expected, the momentum might not last, thus incentivizing safe stocks. 
Via InvestorPlace
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
BioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy Trial
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced overall survival (OS) data from its Phase 2 trial of BXCL701 in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients wi 
Via Benzinga
Merck to Participate in the Jefferies London Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Mizuho's Top Stock Picks For November Revealed
As trading for November begins, Mizuho recommends a few stocks for investors to consider. 
Via Benzinga
Down 84% From Its Peak. Is It Finally Time to Buy Moderna?
The vaccine developer's huge profits have turned into heavy losses. 
Via The Motley Fool
3 Trustworthy Blue-Chip Stocks to Buy Now
Considering the economic and geopolitical uncertainty, seek safety in these blue-chip stocks to buy with earnings and dividend growth. 
Via InvestorPlace
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
The company issued below-consensus sales views for 2023 and 2024. 
Via Investor's Business Daily
3 Dividend Stocks That Could Raise Their Payouts in November
Should you add these income-generating stocks to your portfolio? 
Via The Motley Fool
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic. 
Via Talk Markets
Exposures COVID-19
Merck's Blockbuster Cancer Drug Keytruda Secures FDA Approval For Biliary Tract Cancer
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda, in combination with gemcitabine and cisplatin, for locally advanced unresectable or  
Via Benzinga
Exposures Product Safety
Merck to Participate in the UBS BioPharma Conference
From Merck & Co., Inc.
Via Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy
From Merck & Co., Inc.
Via Business Wire
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
In due time, its new partnership with Daiichi Sankyo could be massive. 
Via The Motley Fool
Jim Cramer Says Hold Onto This Tech Stock, But 'You're Not Going To Make A Lot Of Money In It Right Now, Because That Was A Really Terrible Last Quarter'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Corning Incorporated (NYSE: GLW) reported a disappointing quarter. 
Via Benzinga
2 No-Brainer AI Stocks to Buy and One to Run Away From
Artificial intelligence is altering the business landscape and opening up unique AI stocks to buy as well as ones to avoid. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Can Diabetes, Weight-Loss Drugs Get Even Better?
Via Investor Brand Network
Can Diabetes, Weight-Loss Drugs Get Even Better?
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
96 97 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.